Lexeo Therapeutics, Inc.

As of June 11, 2025, the technical trend is mildly bullish, supported by the weekly MACD and KST, despite mixed signals from daily moving averages and a sideways monthly Bollinger Bands.

Lexeo Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $33 million and a market cap of $130.24 million. Key financial metrics include a negative P/E ratio, a 0.00% dividend yield, and a return on equity of -124.05%.

As of Jun 18, Lexeo Therapeutics, Inc. has a market capitalization of 130.24 million, with net sales of 0.00 million and a net profit of -109.31 million over the last four quarters. The company reported shareholder's funds of 116.84 million and total assets of 149.92 million as of Dec 24.